Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 14.74
(1.03%)
CNY 14.74
(1.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 697.99 Million CNY | 20.8% |
| 2022 | 556.81 Million CNY | -5.04% |
| 2021 | 604.56 Million CNY | 195.85% |
| 2020 | 178.28 Million CNY | -48.5% |
| 2019 | 405.15 Million CNY | 11.08% |
| 2018 | 371.03 Million CNY | 8.88% |
| 2017 | 341.32 Million CNY | 7.19% |
| 2016 | 316.24 Million CNY | 7.07% |
| 2015 | 293.69 Million CNY | 15.15% |
| 2014 | 258.44 Million CNY | 15.94% |
| 2013 | 222.39 Million CNY | 32.14% |
| 2012 | 169.07 Million CNY | 36.15% |
| 2011 | 125.7 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 154.4 Million CNY | -16.06% |
| 2024 Q3 | 153.01 Million CNY | -9.86% |
| 2024 Q2 | 182.02 Million CNY | 10.08% |
| 2023 Q3 | 162.19 Million CNY | -3.47% |
| 2023 Q4 | 203.81 Million CNY | 25.66% |
| 2023 FY | - CNY | 20.8% |
| 2023 Q1 | 140.49 Million CNY | -18.33% |
| 2023 Q2 | 168.02 Million CNY | 19.6% |
| 2022 FY | - CNY | -5.04% |
| 2022 Q4 | 172.02 Million CNY | 25.82% |
| 2022 Q3 | 136.72 Million CNY | 22.82% |
| 2022 Q2 | 111.32 Million CNY | -14.38% |
| 2022 Q1 | 130.02 Million CNY | -7.07% |
| 2021 Q1 | 157.71 Million CNY | 167.62% |
| 2021 Q2 | 167.08 Million CNY | 5.94% |
| 2021 FY | - CNY | 195.85% |
| 2021 Q3 | 128.67 Million CNY | -22.99% |
| 2021 Q4 | 139.91 Million CNY | 8.74% |
| 2020 Q4 | 58.93 Million CNY | -25.86% |
| 2020 Q3 | 79.48 Million CNY | 161.58% |
| 2020 Q2 | 30.38 Million CNY | 86.38% |
| 2020 FY | - CNY | -48.5% |
| 2020 Q1 | 16.3 Million CNY | -88.12% |
| 2019 Q2 | 90.9 Million CNY | 29.98% |
| 2019 FY | - CNY | 11.08% |
| 2019 Q4 | 137.17 Million CNY | 39.43% |
| 2019 Q3 | 98.38 Million CNY | 8.23% |
| 2019 Q1 | 69.93 Million CNY | -42.74% |
| 2018 Q2 | 71.87 Million CNY | 7.39% |
| 2018 Q3 | 95.94 Million CNY | 33.49% |
| 2018 FY | - CNY | 8.88% |
| 2018 Q1 | 66.92 Million CNY | -39.28% |
| 2018 Q4 | 122.13 Million CNY | 27.3% |
| 2017 Q3 | 86.77 Million CNY | 27.69% |
| 2017 Q4 | 110.22 Million CNY | 27.03% |
| 2017 FY | - CNY | 7.19% |
| 2017 Q1 | 64.44 Million CNY | -31.08% |
| 2017 Q2 | 67.95 Million CNY | 5.45% |
| 2016 Q1 | 73.68 Million CNY | -19.66% |
| 2016 Q2 | 67.21 Million CNY | -8.78% |
| 2016 FY | - CNY | 7.07% |
| 2016 Q4 | 93.5 Million CNY | 22.92% |
| 2016 Q3 | 76.06 Million CNY | 13.18% |
| 2015 Q2 | 66.57 Million CNY | 5.09% |
| 2015 Q1 | 63.34 Million CNY | -3.47% |
| 2015 Q4 | 91.7 Million CNY | 34.04% |
| 2015 FY | - CNY | 15.15% |
| 2015 Q3 | 68.41 Million CNY | 2.77% |
| 2014 Q4 | 65.62 Million CNY | 0.46% |
| 2014 Q2 | 65.11 Million CNY | 21.16% |
| 2014 Q1 | 53.73 Million CNY | -7.67% |
| 2014 FY | - CNY | 15.94% |
| 2014 Q3 | 65.32 Million CNY | 0.33% |
| 2013 FY | - CNY | 32.14% |
| 2013 Q4 | 58.2 Million CNY | 13.55% |
| 2013 Q3 | 51.25 Million CNY | 0.0% |
| 2012 FY | - CNY | 36.15% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 62.478% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 75.479% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -141.654% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | -46.941% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | -7.056% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 18.756% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -195.656% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 2.36% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | -97.957% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 1282.85% |